Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Zenas BioPharma is raising $118,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Hua Mu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Zenas BioPharma
Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and delivery of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep portfolio of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases.

To learn more about Zenas BioPharma, visit http://www.zenasbio.com/

Contact:
Hua Mu, Chief Executive Officer
857-271-2954

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved